PREVALENSI DAN KARAKTERISTIK PASIEN PENYAKIT SYSTEMIC LUPUS ERITHEMATOSUS (SLE) DI POLIKLINIK PENYAKIT DALAM RSUD RADEN MATTAHER JAMBI PERIODE JULI - OKTOBER 2025
Keywords:
Systemic Lupus Erythematosus, karakteristik pasien, prevalensi, RSUD Raden Mattaher, jambiAbstract
Systemic Lupus Erythematosus (SLE) merupakan penyakit autoimun kronik dengan inflamasi multisistem dan variasi manifestasi klinis serta laboratorium. Perbedaan karakteristik pasien di setiap populasi menjadikan penelitian deskriptif penting sebagai dasar evaluasi tatalaksana. Penelitian ini bertujuan untuk menggambarkan karakteristik klinis dan laboratorium pasien SLE di Poliklinik Penyakit Dalam RSUD Raden Mattaher Jambi. Penelitian ini bersifat deskriptif observasional dengan rancangan cross-sectional. Data dikumpulkan melalui wawancara langsung terhadap pasien dan telaah rekam medis, mencakup variabel usia, jenis kelamin, pekerjaan, tempat tinggal, hasil tes laboratorium (ANA dan darah rutin), serta manifestasi klinis. Analisis dilakukan secara univariat untuk menggambarkan distribusi frekuensi setiap variabel. Mayoritas pasien SLE berusia 26–35 tahun (37,5%) dan hampir seluruhnya perempuan (96,9%). Keluhan tersering adalah kelelahan dan artralgia (96,9%). Kelainan laboratorium meliputi hemoglobin rendah (18,8%), hematokrit rendah (21,9%), leukopenia (15,6%), leukositosis (28,1%), trombositopenia (3,1%), dan trombositosis (9,4%). Semua pasien ANA-IF positif (100%). Terapi utama adalah kortikosteroid (100%), imunosupresan (93,8%), antimalaria (46,9%), dan OAINS minimal (3,1%)
Downloads
References
Tsokos GC. Systemic Lupus Erythematosus. N Engl J Med [Internet]. 2011 Dec 1 [cited 2024 Sep 4];365(22):2110–21. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra1100359
Baldovino S, Rollino C. Epidemiology of Systemic Lupus Erythematosus. Rare Dis Immune Syst. 2016;30(2):5–21.
Zuleika Putri Maharani S, Yuliasih D, Budiono Notopuro P, Diah Rahmawati L. The Pattern of Hematological Manifestations in Systemic Lupus Erythematosus Patients at Dr. Soetomo General Academic Hospital Surabaya. Int J Res Publ. 2022;111(1):229–35.
Akiko Ohta, Masaki Nagai, Motoko Nishina, Hiroyuki Tomimitsu HK. Age at onset and gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol [Internet]. 2013;23(4):759–764. Available from: https://doi.org/10.3109/s10165-012-0733-7
Bindroo MA, Majid N, Ekbote G, Raval D, Negalur NV, Mendiratta N, Bajad S GR. Late Onset Systemic Lupus Erythematosus - Clinical and Autoantibody Profile and its Comparison with Young Onset Systemic Lupus Erythematosus. Mediterr J Rheumatol. 2023;34(3):454–9.
Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Systemic lupus erythematosus incidence and prevalence in a large population-based study in northeastern Italy. Rheumatol (United Kingdom). 2023;62(8):2773–9.
Bultink IEM, Turkstra F, Dijkmans BENAC, Voskuyl AE. High Prevalence of Unemployment in Patients with Systemic Lupus Erythematosus : Association with Organ Damage and Health-Related Quality of Life. 2008;1053–7.
EDWARD YELIN, PhD, LAURA TRUPIN, MPH, PATRICIA KATZ, PhD LC, MD, MPH, JINOOS YAZDANY, MD, MPH, JOANN GILLIS, MD, and PETER PANOPALIS M. Work Dynamics Among Persons With Systemic Lupus Erythematosus. Arthritis Rheum. 2007;57(1):56–63.
Nyoman APD, Tjokarda IAS, Pande KK. Karakteristik Manifestasi Klinis Pasien Sistemik Lupus Eritematosus Di Poliklinik Rematologi Rsup Sanglah Periode Juni –September 2018. J Med Udayana [Internet]. 2020;9(5):1–6. Available from: https://ojs.unud.ac.id/index.php/eum
Sterling KL, Gallop K, Swinburn P, Flood E, French A, Sawah S Al, et al. Patient-reported fatigue and its impact on patients with systemic lupus erythematosus. Lupus. 2014;23(2):124–32.
Kawka L, Schlenckerv A, Mertz P, Martin T, Arnaud L. Fatigue in systemic lupus erythematosus: An update on its impact, determinants and therapeutic management. J Clin Med. 2021;10(17).
Fandika RA, Sukendra DM. Hubungan Antara Tingkat Keparahan Penyakit, Aktivitas Fisik Dan Kualitas Tidur Terhadap Kelelahan Pada Pasien Systemic Lupus Erythematosus (Sle). Unnes J Public Heal. 2016;5(3):221.
Azizoddin DR, Gandhi N, Weinberg S, Sengupta M, Nicassio PM, Jolly M. Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus. 2019;28(2):163–73.
Tomičević LS, Barešić M, Mayer M, Anić B. Musculoskeletal Manifestations of Systemic Lupus Erythematosus. Acta Clin Croat. 2023;62(4):714–23.
Dégboé B*, Atadokpede 1, Sémikenké Kazoza S, Agbodandé A, Zomaletho Z K dan melakukan APF. Systemic Lupus Erythematosus : Immunologic Profile Associated to Clinical Manifestations in 30 Patients in the University Hospital of Cotonou , Benin. 2017;5(1):3–8.
Li H, Zheng Y, Chen L, Lin S. Antinuclear antibody-negative systemic lupus erythematosus: How many patients and how to identify? Arch Rheumatol. 2022;37(4):626–34.
Sasidharan PK, Bindya M, Sajeeth Kumar KG. Hematological Manifestations of SLE at Initial Presentation: Is It Underestimated? ISRN Hematol. 2012;2012:1–5.
Gulati S, Kumar V, Rawat P, Chawla K, Dessai R, Jain S. Study of hematological profile of systemic lupus erythematosus. Int J Res Med Sci [Internet]. 2023;11(9):3332–5. Available from: https://dx.doi.org/10.18203/2320-6012.ijrms20232788
Lu W, Zhong Y, Zhang Y, Liu Z, Xue L. The Clinical Characteristics of Leukopenia in Patients with Systemic Lupus Erythematosus of Han Ethnicity in China: A Cross-Sectional Study. Rheumatol Ther [Internet]. 2021;8(3):1177–88. Available from: https://doi.org/10.1007/s40744-021-00336-6
Jiang N, Li M, Zhang M, Xu J, Jiang L, Gong L, et al. Chinese SLE Treatment and Research group ( CSTShobha V, Rajasekhar L, Bhat V, Mathew AJ, Kavadichanda C, Rathi M, Gupta R, Selvam S, A.A. (2023) ‘Severe thrombocytopenia is associated with high mortality in systemic lupus erythematosus-analysis from India. 2019;1–16.
Shobha V, Rajasekhar L, Bhat V, Mathew AJ, Kavadichanda C, Rathi M, Gupta R, Selvam S AA. Severe thrombocytopenia is associated with high mortality in systemic lupus erythematosus-analysis from Indian SLE Inception cohort for Research (INSPIRE). clin rheumatol [Internet]. 2023;42(9):2279–85. Available from: 10.1007/s10067-023-06641-5
Park HJ, Kang M il, Kang Y, Chung S jin, Lee SW, Park YB, et al. Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide. J Korean Med Sci. 2013;28(3):472–5.
Yuce Inel T, Uslu S, Demirci Yildirim T, Gulle S, Sen G. Hematologic Involvement in Systemic Lupus Erythematosus: Clinical Features and Prognostic Implications in a Hematology-Referred Cohort. J Clin Med. 2025;14(20):1–10.
Masurkar PP, Reckleff J, Princic N, Limone B, Schwartz H, Karis E, et al. Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA. Lupus Sci Med. 2024;11(2):1–8.
Frodlund M, Jönsen A, Remkus L, Telg G, Söderdahl F, Leonard D. Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality—a national cohort study. Rheumatol (United Kingdom). 2024;63(4):1104–12.
M Y Karim 1, P Alba, M-J Cuadrado, I C Abbs, D P D’Cruz, M A Khamashta GRVH. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatol. 2002;8.
Bhowmik S. Steroid Use Higher than Expected in Patients with Lupus. medcentral. 2024;
Horizon AA, Wallace DJ. Risk: Benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004;3(4):273–8.
Østensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2001;10(3):135–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Najla Lulu Khanza, Fenny Febrianty, Rita Halim
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
